Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves aimed at the brain could ease Parkinson's symptoms

NCT ID NCT07207122

Symptom relief Sponsor: Sanmai Technologies PBC dba Sanmai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests a new device that uses focused ultrasound waves on the brain to see if it can safely improve movement problems in people with Parkinson's disease. About 60 adults with Parkinson's will receive either real or fake (sham) ultrasound treatments. Researchers will measure changes in motor skills and watch for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 22 to 80 years. * Diagnosis of idiopathic Parkinson's disease. * MDS-UPDRS Part III score ≥25 in OFF-medication state at baseline. * Stable dopaminergic therapy for at least 30 days prior to enrollment. * English proficiency. * Normal or corrective hearing and vision. * Ability to provide informed consent (or availability of an LAR) and comply with protocol requirements. Exclusion Criteria: * Atypical or secondary Parkinsonism. * Prior deep brain stimulation or intracranial surgery. * MoCA score \<23. * Severe psychiatric illness (e.g., psychosis, suicidality, untreated major depression). * History of seizure or intracranial pathology. * Significant neurologic disease (e.g. brain tumor, multiple sclerosis) * Contraindication to MRI or ultrasound. * Unstable systemic medical conditions. * Active malignancy or history of cancer within the past 5 years. * Pregnancy or breastfeeding. * Participation in another interventional trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer&#39;S are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction Lewy body dementia Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer&#39;S Alzheimer&#39;S disease (AD) Mild cognitive impairment Parkinson disease Parkinson&#39;S disease (PD) Parkinson&#39;S disease dementia Parkinson&#39;S disease dementia (PDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Radial Midtown Manhattan

    RECRUITING

    New York, New York, 10018, United States

  • The Regenesis Project

    RECRUITING

    Santa Monica, California, 90403, United States

  • UF - McKnight Brain Institute

    RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Arizona

    RECRUITING

    Tucson, Arizona, 85719, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.